Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A2P4LJ5
Thu, 18.04.2024
PharmaSGP Holding SE
Publication of inside information in accordance with Article 17 of Regulation (EU) No 596/2014
PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
Gräfelfing, April 18, 2024 – The Management Board and Supervisory Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5) will propose to this year's Annual General Meeting [ … ]
Tue, 14.03.2023
PharmaSGP Holding SE
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
PharmaSGP Holding SE releases forecast for full year 2023
Gräfelfing, March 14, 2023 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before intere [ … ]
Tue, 14.03.2023
PharmaSGP Holding SE
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
PharmaSGP Holding SE releases forecast for full year 2023
Gräfelfing, March 14, 2023 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has agreed on the forecast for consolidated revenue and adjusted consolidated earnings before intere [ … ]
Tue, 03.01.2023
PharmaSGP Holding SE
PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro
Gräfelfing, Germany, January 3, 2023 - The Management Board of PharmaSGP Holding SE (ISIN DE000A2P4LJ5, „PharmaSGP“) has decided today, with the approval of the Supervisory Board, utilizing the authorization of the General Meeting of May 28, 2020, to buy-back [ … ]
Thu, 10.11.2022
PharmaSGP Holding SE
PharmaSGP Holding SE raises forecast for FY 2022
Gräfelfing, November 10, 2022 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has decided today, based on an evaluation of actual business data completed today, to raise the forecast for group revenue and adjusted group earnings before interest, taxes, depreciation and amortizati [ … ]
Thu, 10.11.2022
PharmaSGP Holding SE
PharmaSGP Holding SE raises forecast for FY 2022
Gräfelfing, November 10, 2022 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has decided today, based on an evaluation of actual business data completed today, to raise the forecast for group revenue and adjusted group earnings before interest, taxes, depreciation and amortizati [ … ]
Wed, 15.09.2021
PharmaSGP Holding SE
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio
Gräfelfing, September 15, 2021 - Following the scheduled closing on August 31, 2021 of the agreement signed with the GlaxoSmithKline Group on the acqui [ … ]
Tue, 15.06.2021
PharmaSGP Holding SE
Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
At the same time publication pursuant to § 111c of the German Stock Corporation Act (Aktiengesetz)
PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt and Kamol) from GSK
Gräfelfing, June 15, 2021 - PharmaSGP GmbH, a subsidiary of P [ … ]
Fri, 27.11.2020
PharmaSGP Holding SE
PharmaSGP Holding SE: Adjustment of full-year forecast 2020 due to expected weaker fourth quarter following COVID-19-related restrictions
Gräfelfing, November 27, 2020. Based on an evaluation of current data on the business development to date and the expected further business performance of the PharmaSGP Group in the fourth quarter of 2020, which [ … ]